Research

Make cancer therapy safe and effective

Publications:
Mansurov A, Ishihara J, Hosseinchi P, Potin L, Marchell TM, Ishihara A, Williford J-M, Alpar AT, Raczy MM, Gray LT, Swartz MA, Hubbell JA, 2020, Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours, Nature Biomedical Engineering, Vol: 4, Pages: 531-543


Williford J-M, Ishihara J, Ishihara A, Mansurov A, Hosseinchi P, Marchell TM, Potin L, Swartz MA, Hubbell JA, 2019, Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy, Science Advances, Vol: 5, Pages: 1-15, ISSN: 2375-2548


Sasaki K, Ishihara J, Ishihara A, Miura R, Mansurov A, Fukunaga K, Hubbell JA, 2019, Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy, Science Advances, Vol: 5, Pages: 1-12, ISSN: 2375-2548


Ishihara J, Ishihara A, Sasaki K, Lee SS-Y, Williford J-M, Yasui M, Abe H, Potin L, Hosseinchi P, Fukunaga K, Raczy MM, Gray LT, Mansurov A, Katsumata K, Fukayama M, Kron SJ, Swartz MA, Hubbell JA, 2019, Targeted antibody and cytokine cancer immunotherapies through collagen affinity, Science Translational Medicine, Vol: 11, Pages: eaau3259-eaau3259, ISSN: 1946-6234

Ishihara J, Ishihara A, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA, 2018, Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity, Molecular Cancer Therapeutics, Pages: molcanther.0091.2018-molcanther.0091.2018, ISSN: 1535-7163

Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P, Galliverti G, Swartz MA, Hubbell JA, 2017, Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events, Science Translational Medicine, Vol: 9, Pages: eaan0401-eaan0401, ISSN: 1946-6234